Drug-resistant tuberculosis medical therapy: Difference between revisions
| Line 59: | Line 59: | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: # | | style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small>Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.<ref name="WHO 2013"> {{Citeweb | url= http://www.who.int/tb/publications/tb_treatmentguidelines/en/| Title= 2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes}}</ref></small> | ||
|} | |} | ||
|} | |} | ||
Revision as of 15:37, 17 September 2014
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Drug-resistant tuberculosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Drug-resistant tuberculosis medical therapy |
|
Risk calculators and risk factors for Drug-resistant tuberculosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Multiple Drug-Resistant (MDR) Tuberculosis
- MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs.
- Medical treatment for MDR-TB consists of at least 4 drugs that have shown effectiveness against MDR.
- Treatment duration will depend on the culture results. The duration of therapy should be > 18 months after culture is negative.
- Chronic cases with severe pulmonary disease may require more than 24 months of therapy.
|
MDR Tuberculosis ▸ Adults ▸ Children |
|
Extensively Drug-Resistant XDR Tuberculosis
XDR-TB is defined as resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables (amikacin, capreomycin, and kanamycin).
|
XDR Tuberculosis ▸ Adults ▸ Children |
|